Improving Cash GenerationThe company recorded positive EBITDA and free cash flow in 2025, reversing prior cash losses. Durable positive operating cash flow supports reinvestment in processing capacity and IP monetization, reducing reliance on external financing over the next several quarters.
Low And Improving LeverageLeverage has fallen materially from earlier peaks, leaving a stronger capital cushion and greater balance-sheet flexibility. Low debt levels reduce interest burden and permit strategic investments or licensing support without immediate refinancing risk over the medium term.
Proprietary IP And Scalable Business ModelThe firm’s proprietary extraction and purification technologies plus an IP-licensing strategy create structural advantages: scalable revenue via ingredient sales and royalties, higher margins on proprietary processes, and barriers to entry that support durable differentiation.